19 results about "Astrocyte" patented technology

The present application relates to the field of biotechnology, in particular to biomarkers for predicting the risk of central nervous system paralymphoid dysfunction and application thereof. The biomarkers for predicting the risk of central nervous system paralymphoid dysfunction are astrocyte-derived migratory bodies isolated from peripheral blood. An increase in the number of peripheral blood astrocyte-derived migratory bodies can be used as a marker for predicting the risk of paralymphoid dysfunction. The peripheral blood astrocyte migratory bodies provided by the present application can be used as an index for predicting the risk of central nervous system paralymphoid dysfunction, which can help to prompt central nervous system paralymphoid dysfunction when a patient cannot complete a head magnetic resonance DTI-ALPS sequence scan. The peripheral blood astrocyte migratory bodies can help doctors to formulate appropriate prevention or treatment plans for patients in combination with clinical symptoms, medical history or other examination information in a timely manner, and have extremely important clinical application potential and value.

The invention discloses a strain of lactobacillus acidophilus for treating chronic cerebral ischemia, which is preserved in the China Center for Type Culture Collection (CCTCC) and has the preservation number of CCTCC NO: M 20251505. Animal experiments show that the strain can reduce the death rate of chronic cerebral ischemia model mice and improve neurological impairment, motion coordination and spatial learning and memory ability of the chronic cerebral ischemia model mice. Mechanism research shows that the strain can increase histone acetylation and BDNF secretion by inhibiting the activity of astrocyte HDAC1, and meanwhile, can inhibit an NF-kappa B signal channel and reduce inflammatory factor release by activating a microglial cell GPR120 receptor, so that a neuroprotective effect is achieved through an'intestine-brain axis'. The invention provides a new candidate strain for the development of microbial preparations for preventing and / or treating chronic cerebral ischemia and related cognitive impairment.

Provided is a structure composed of a cell population comprising endothelial cells, astrocytes and pericytes, and a 3D (three dimensional) cell growth material within which the cell population is located. The structure has a TEER value of at least 450 Ω / cm2. The cells of the structure may be derived from the brain. The cells may be human cells, and in particular may be primary derived non-immortalised cells. The structure is particularly suited for use in a model of the blood brain barrier, and the invention also provides such a model. The structure is located in a container, in which it separates a first chamber located on a first side of the structure and a second chamber located on a second side of the structure. The first and second chambers respectively contain first and second liquids in contact with first and second sides of the structure. The liquids mimic the brain extracellular fluid and the blood. The blood brain barrier model provided may be used in models of brain disease, and to investigate uptake of agents into the brain or diseased brain.

The present invention relates to new agents useful for stimulating uptake of glucose and release of lactate by astrocytes. The invention further relates to methods of preparation, formulations and therapeutic uses of those agents, notably for the prevention and / or treatment of neurological disorders with brain energy hypometabolism, in particular neurodegenerative, neurometabolic and psychiatric disorders or improving cognitive and memory functions.

The invention relates to an in vitro method of generating a murine cerebral organoid cell culture model, comprising cultivating murine neural stem cells obtained from an adult mouse until neurospheres have formed, and subsequently differentiating said neurospheres, thereby generating a murine cerebral organoid cell culture model. The invention further relates to an in vitro murine cerebral organoid cell culture model comprising mature astrocytes, oligodendrocytes and / or neurons produced according to the method of the invention and its use for drug or toxicity screenings or for studying neurological diseases. In other aspects the invention further relates to kits, cell culture media and supplement compositions comprising components to be used in the context of the present invention.

The present application relates to a kind of pentosus PP90 for preventing and treating alcoholic nerve injury and its application, wherein pentosus PP90 is preserved in China Microbial Culture Collection Center, and the preservation number is CGMCC NO.32034.The fermentation product of the pentosus PP90 can degrade the alcoholicity of alcohol, can produce ethanol dehydrogenase and acetaldehyde dehydrogenase, can improve the viability of nerve cell, can regulate the expression of cytokine, can inhibit the activation of astrocyte, can regulate the expression of brain-derived neurotrophic factor, can improve the level of disturbed neurotransmitter, and can be used for preparing product for preventing and treating alcoholic nerve injury or improving alcoholic nerve injury.

The application provides semi total flavonoids of Liquidambar, which is obtained by using stems of Liquidambar cathayensis Hung T.Chang as raw materials and adopting ultrasonic-assisted low eutectic solvent extraction, wherein the yield of the total flavonoids is 71.95%±6.49%. The application also provides a preparation method and application of the semi total flavonoids of Liquidambar. The semi total flavonoids of Liquidambar have significant antioxidant activity, can be used for nerve protection, can be used for treating cerebral ischemia or anti-ischemic stroke, can improve cerebral ischemic nerve function injury, can reduce cerebral infarction volume, can reduce neuron damage degree, can reduce activation of astrocytes, can reduce expression level of apoptotic proteins, can protect neurons and synapses, and can protect vascular endothelial cells. The drug efficacy is clear and controllable, is equivalent to that of positive drug nimodipine, can reach significant drug efficacy at a low dose, is safer in clinical use, and provides a new selection for clinic.

The invention provides application of a substance for inhibiting HSP90 alpha-K408 site lactic acid in astrocytes in epilepsy diseases. The HSP90 alpha-K408 site is the 408th site of an amino acid sequence shown in SEQ ID NO: 1. According to the invention, HSP90 alpha-K408 site lactic acid in astrocyte is taken as a treatment target of epilepsy, the polypeptide for inhibiting HSP90 alpha-K408 site lactic acid in astrocyte is provided, and mouse experiments prove that the polypeptide for inhibiting HSP90 alpha-K408 site lactic acid in astrocyte has an adjusting effect on the content of glutamic acid and glutamine; the number of neuronal cells can be effectively regulated and controlled, and epilepsy diseases can be effectively relieved and treated.

The invention relates to the technical field of preparation and application of traditional Chinese medicine compositions, and particularly discloses a traditional Chinese medicine composition for treating Alzheimer's disease and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 3-9 parts of ginseng, 3-10 parts of morinda officinalis, 6-12 parts of dogwood, 3-10 parts of rhizoma acori graminei, 3-10 parts of polygala tenuifolia, 3-6 parts of rhodiola rosea, 3-6 parts of China rose, 2-3 parts of hypericum perforatum, 3-6 parts of saussurea involucrate, 9-15 parts of cortex lycii radicis, 3-12 parts of golden cypress and 1-5 parts of agilawood. The traditional Chinese medicine composition provided by the invention accords with the traditional Chinese medicine treatment concept of tonifying deficiency and filling marrow, inducing resuscitation and soothing nerves, dredging collaterals and eliminating evil, and tonifying spleen and assisting transportation, not only can relieve damage of neurons, but also can reverse alzheimer disease related disorder signal channels in neuronal cells, microglial cells and astrocytes.

The application belongs to the technical field of biological medicine, and particularly relates to the use of SH2 domain-containing protein tyrosine phosphatase 1 (SHP1) in the preparation of a drug for treating chronic pain, in particular to the use of SHP1 in the preparation of a drug for treating chronic pain by regulating the morphology of spinal cord astrocytes, the integrity of the blood-spinal cord barrier and the STAT1-CXCL10-CXCR3 neuroimmune signal axis, and a chronic pain treatment strategy based on the signal axis. The application first discloses that SHP1 in spinal cord astrocytes directly dephosphorylates STAT1, inhibits the transcription of CXCL10 and the subsequent infiltration of T lymphocytes into the spinal cord, and discloses the core analgesic mechanism, thereby establishing SHP1 as a new target for treating chronic pain, and opening up a new way for the precise treatment of clinical chronic pain, especially neuropathic pain.

Oligonucleotide conjugates are provided herein that inhibit or reduce expression of target genes in the astrocytes of the central nervous system. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and / or conditions associated with expression of an astrocyte target gene in the CNS.

This application discloses the application of Bcl11a in the preparation of drugs for nerve injury repair, belonging to the field of biomedical technology. The nerve injury is a central nervous system injury. Overexpression of Bcl11a promotes the transdifferentiation of an intermediate state astrocyte in the cerebral cortex into pyramidal neurons. Using Bcl11a as a molecular intervention target, targeting the M1 motor area of ​​the cerebral cortex, overexpression of Bcl11a in astrocyte subset 2 promotes the reprogramming of astrocytes into pyramidal neurons, promoting the repair of central nervous system injury. Using spatial transcriptome sequencing technology and single-cell sequencing technology, the dynamic trajectory between astrocytes and pyramidal cells was depicted, supporting the transformation of an intermediate transitional state astrocyte in the cortex into pyramidal cell subset 3 after spinal cord injury, indicating that Bcl11a and Zmart4 are key transcription factors in the connection between pyramidal cells and glial cells.

The invention relates to scutellarin-loaded brain tissue exosome nanoparticles and application thereof in preparation of a medicine for treating diseases by penetrating through a blood brain barrier, and belongs to the technical field of medicines. Brain tissue exosome nanoparticles loaded with scutellarin are added into mouse microglial cells, astrocytes and brain microvascular endothelial cells, so that the nanoparticles can regulate the polarization of the microglial cells caused by PRV infection, remarkably inhibit the expression of M1 type microglial cells CD86, promote the expression of M2 type microglial cells CD 206, inhibit the expression of the PRV infection, and inhibit the PRV infection. The anti-inflammatory effect is achieved; through in-vitro Transwell blood brain barrier and blood brain barrier penetration test of the exosome of a living brain tissue model, it is obtained that the brain tissue exosome can enhance the brain delivery efficiency of scutellarin. The scutellarin-loaded brain tissue exosome nanoparticles provided by the invention solve the problems of difficult scutellarin blood brain barrier penetration and low bioavailability, and have important practical significance in prevention and control of porcine pseudorabies.

The present invention addresses the problem of providing: a blood-brain barrier model that can be produced in a relatively simple manner and in which a physiological barrier function and selective permeability are reproduced; and a method for producing the blood-brain barrier model.　A blood-brain barrier model in which a physiological barrier function and selective permeability are reproduced can be produced in a relatively simple manner in a blood-brain barrier model having three cell layers of perisites, astrocytes, and vascular endothelial cells by culturing vascular endothelial cells so as to form a sheet structure on the surface of a porous membrane and so that perisites are present in an internal structure layer of the porous membrane.

The application relates to the technical field of biological medicine, and discloses application of a TYK2 inhibitor in preparation of a medicine for preventing and / or treating SAE. The application provides application of a TYK2 inhibitor in preparation of a medicine for preventing and / or treating sepsis-associated encephalopathy (SAE). The application first applies the TYK2 inhibitor to blood-brain barrier damage caused by LPS, proves the protective effect of the TYK2 inhibitor (including deuterium canexetil and Tl1041) on endothelial cells in the blood-brain barrier and microglial cells, astrocytes and neuron cells in brain tissues, indicates that the TYK2 inhibitor can relieve blood-brain barrier damage caused by LPS, and points out a possible direction for applying the TYK2 inhibitor to treat sepsis-associated encephalopathy and blood-brain barrier damage caused by the sepsis-associated encephalopathy in the clinic.

The invention belongs to the technical field of biological medicines, and relates to application of a histone deacetylase inhibitor HDACi in preparation of a medicine for preventing and / or treating hyperammonemia-induced encephalopathy. According to the invention, a histone deacetylase inhibitor HDACi is used as a new medicine, the HDACi can enter a central nervous system, and the GS is triggered to be degraded through a proteasome mediated by CRBN E3 ubiquitin ligase by improving the acetylation level of a key enzyme, namely glutamine synthetase (GS), of astrocytes, so that the GS protein abundance is reversibly reduced, and the GS protein abundance is reduced. The application has the advantages that pathological accumulation of toxic metabolite glutamine can be reduced from the source, cerebral edema, autophagy-lysosomal dysfunction, neuroinflammation and neuron injury caused by the pathological accumulation can be synchronously improved, severe neurotoxicity such as persistent enzyme inhibition and acute epilepsy caused by irreversible inhibitors such as MSO can be avoided, clinical transformation risks can be obviously reduced, and the safety is high.

The invention belongs to the technical field of biological medicines, and particularly relates to a glucocorticoid-induced abnormal feeding behavior marker, a medicine and application of the glucocorticoid-induced abnormal feeding behavior marker. According to the application disclosed by the invention, research tests show that the expression quantity of GLUT2 in abnormal ingestion behaviors induced by glucocorticoids is remarkably reduced, so that the specific target GLUT2 of the hypothalamic astrocytes is provided, after the hypothalamic astrocytes Glut2 are subjected to AAV targeted overexpression, the GCs-induced ingestion increase is remarkably reduced, the body weight is also remarkably reduced, and the GLUT2 can be used for preparing the specific target GLUT2 of the hypothalamic astrocytes. The peripheral metabolism index is kept stable, and other metabolism-related side effects are avoided. A large amount of experimental data proves that the MSC-EVs has a remarkable curative effect on SLE patients and is safe, animal experimental results show that no obvious adverse reaction is observed in the process that SLE mice receive the MSC-EVs, and meanwhile, the MSC-EVs has certain advantages in SLE disease control.

The invention discloses an astrocyte memristive network driven time sequence analysis and dynamic security method, system and device and a medium, and belongs to the technical field of computer vision and information security, and the method comprises the steps: collecting a video stream, and extracting a human skeleton sequence; performing space-time alignment evaluation on the skeleton sequence and a standard template, and identifying an abnormal action; constructing a quadruple synaptic network comprising Chay neurons, HR neurons, astrocytes and memristors, and dynamically adjusting electrical coupling parameters through gesture recognition to generate chaotic signals; extracting multi-dimensional features from the chaotic signal, and generating a key stream through Hash enhancement and key expansion; encrypting the video data by using the key stream; and generating a scoring suggestion. Lightweight real-time encryption is realized through the biologically inspired chaotic neural network, the problem of high calculation complexity of a traditional encryption algorithm is solved, real-time performance and safety are both considered, gesture dynamic control is supported, and the method is suitable for scenes such as rehabilitation training and posture correction.

The present disclosure provided methods and compositions for generating a triple cell culture comprising neurons, astrocytes, and microglia. The method includes providing neurons, astrocytes, and microglial cells or precursors, and culturing them under conditions that support survival, maturation, and functional interaction. In some embodiments, the cells are derived from pluripotent stem cells and seeded in defined ratios. The cultures are suitable for modeling central nervous system function, disease processes, and for evaluating candidate therapeutic agents. Also disclosed are variations of the culture system including use of reporter genes, cryopreserved cell components, three-dimensional formats, and high-throughput assay configurations.